Sun Pharmaceutical Industries Ltd.

In a bid to control costs that have spiralled since it bought Ranbaxy Laboratories, Sun Pharmaceutical Industries is reportedly looking to divest a manufacturing plant in Ireland.

The world’s fifth largest generic drugmaker has been working on resolving issues at Ranbaxy's India-based drug manufacturing sites, all of which have been banned from exporting to its largest market, the United States, over quality control issues.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable the company to deliver quality products in a timely manner at affordable prices.